trial

A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia

NCTId NCT04136873
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 130 (actual)
Sponsored by Cerevel Therapeutics, LLC
Primary completion 2021-05-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
130 (actual)
Study type
Interventional
Allocation
Randomized
Model
Sequential
Masking
Triple
Start
2019-10-15
Primary completion
2021-05-07
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Emraclidine

Sponsors

Cerevel Therapeutics, LLCLead Sponsor

Investigators

1
Matthew Leoni, MD, MBAStudy Director

Sites

5 total
Bentonville, United StatesLittle Rock, United StatesLemon Grove, United StatesLong Beach, United StatesMarlton, United States

Facts & assertions

4 sourced
Enrollment
130
Phase
PHASE1
Primary Completion Date
2021-05-07
Status
COMPLETED
relationships
The graph out of here
drug
Emraclidine
drug
lead_sponsor
Cerevel Therapeutics, LLC
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Matthew Leoni, MD, MBA
person